Metformine Eg Labo

Metformin, the active ingredient in Metformine Eg Labo, is a biguanide presented as an oral tablet for oral use. It is used to improve glycaemic control in adults with type 2 diabetes mellitus.\n\nGNH India supplies Metformine Eg Labo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformine Eg Labo (metformin) belongs to the biguanide class and is employed in the management of disorders related to insulin resistance and hyperglycaemia.\n\nType 2 diabetes mellitus: improves blood glucose control and reduces HbA1c levels.\nPrediabetes: helps delay progression to overt diabetes by enhancing insulin sensitivity.\nPolycystic ovary syndrome (PCOS): reduces insulin resistance and may improve menstrual regularity.

Metformine Eg Labo is generally well tolerated, but adverse reactions can occur.\n\nCommon Side Effects:\n- Nausea\n- Diarrhoea\n- Abdominal discomfort\n- Metallic taste\n- Loss of appetite\n- Flatulence\n\nSerious or Rare Side Effects:\n- Lactic acidosis (life‑threatening)\n- Severe skin reactions such as Stevens‑Johnson syndrome\n- Hepatic dysfunction\n- Vitamin B12 deficiency with long‑term use\n- Hypoglycaemia when combined with other glucose‑lowering agents\n- Acute pancreatitis (rare)

Before initiating Metformine Eg Labo, several safety considerations should be reviewed.\n\nRenal function monitoring: assess eGFR and adjust dose or discontinue if severely impaired.\nHepatic function assessment: avoid use in active liver disease due to lactic acidosis risk.\nRisk of lactic acidosis: evaluate for conditions that predispose, such as hypoxia or sepsis.\nConcomitant medication review: avoid drugs that may increase metformin levels or lactic acidosis risk.\nPatient education: inform about gastrointestinal symptoms and advise to report persistent issues.\nStore at ambient temperature: keep in original packaging, protect from moisture and heat.

Metformine Eg Labo may interact with several medicines, requiring attention to avoid adverse outcomes.\n\nMajor Interactions (Avoid):\n- Iodinated contrast agents: can precipitate acute renal failure and lactic acidosis.\n- Cimetidine: may increase metformin plasma concentrations.\n- Alcohol excess: heightens risk of lactic acidosis.\n\nModerate Interactions (Monitor Closely):\n- Beta‑blockers: may mask hypoglycaemia symptoms.\n- Diuretics: can affect renal clearance of metformin.\n- NSAIDs: may impair renal function and increase metformin exposure.